Mario Boccadoro

TL;DR: It is demonstrated that CLL cells from TP53-disrupted (TP53dis) patients have constitutively higher expression levels of the α-subunit of Hif-1 (HIF-1α) and increased HIF- 1 transcriptional activity compared to the wild-type counterpart, providing preclinical evidence to stimulate further investigation into use as a potential new drug in CLL.

TL;DR: A phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma and an international randomised, open-label, phase 3 study are described.

TL;DR: Bortezomib, with its unique mechanism of action and demonstrated clinical efficacy and safety, should be considered as standard, early treatment in patients with relapsed multiple myeloma, especially after first relapse, experts concluded.

TL;DR: VMPT-VT was superior to VMP for cases with normal renal function and moderate RI, whereas VMPT -VT failed to outperform VMP in patients with severe RI, although the relatively low number of cases analyzed preclude drawing definitive conclusions.

TL;DR: This prospective, randomized, phase III trial compared VMPT with a maintenance regimen including bortezomib and thalidomide with VMP without a maintenance regiment and induced a high proportion of complete responses (CR) in newly diagnosed myeloma patients.